CollPlant Biotechnologies (CLGN) Corporate presentation summary

Technology platform and product innovation

• Proprietary plant-based technology produces recombinant human collagen (rhCollagen) at mass scale using genetically engineered tobacco plants, offering a xeno-free, highly homogeneous, and biofunctional alternative to animal-derived collagen.

• rhCollagen demonstrates superior safety, biofunctionality, and regenerative properties, making it ideal for tissue repair, organ manufacturing, and medical aesthetics.

• Product pipeline includes injectable and photocurable dermal fillers, 3D bioprinted breast implants, soft tissue repair matrices, and bioinks for 3D bioprinting.

• Photocurable fillers combine rhCollagen and hyaluronic acid, enabling in-situ hardening, enhanced tissue regeneration, and customizable contouring for natural outcomes.

• Bioinks support animal-free drug discovery and tissue modeling, aligning with FDA's move to phase out animal testing.

Strategic partnerships and commercialization

• Exclusive global agreement with AbbVie for dermal and soft tissue fillers, with AbbVie leading development, regulatory, and commercialization efforts.

• Up to $50M in milestone payments and royalties from AbbVie, with $26M already received or committed.

• CollPlant supplies rhCollagen to AbbVie for use in their products.

• Commercial products include VergenixSTR for tendinopathy (marketed in Europe) and Collink3D bioinks for 3D bioprinting.

Market opportunities and clinical validation

• Addressing multi-billion dollar markets in medical aesthetics and breast implants, with dermal filler market valued at $6.3B (2023) and breast implant market at $3B (2024).

• Clinical studies show VergenixSTR achieves 74% clinical success at 3 months and 86% at 6 months for tendinopathy treatment.

• 3D bioprinted breast implants aim to provide a regenerative alternative to silicone implants, addressing safety concerns and FDA alerts.

• Mayo Clinic and Technion studies validate rhCollagen's performance in advanced tissue models and as a superior alternative to animal-derived biomaterials.